Abstract: The present invention relates to a modified yeast strain which is prepared by introducing a vector that expresses HMG-CoA reductase (hydroxymethylglutaryl CoA reductase) and farnesyl pyrophosphate synthase, and a method for producing squalene using the same. More particularly, the present invention relates to Saccharomyces cerevisiae Y2805 modified yeast strain that is transformed with a vector including the HMG1 gene, and ispA or Erg20 gene, and a method for producing squalene with high efficiency by culturing the modified yeast strain.

Abstract: The present invention provides substantially purified or isolated fungi of Nodulisporium spp. or Ascocoryne spp., plants infected with said fungi, organic compounds produced by said fungi, and related nucleic acids, polypeptides and methods.

Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: This invention provides novel enzyme compositions using newly identified and isolated C. lucknowense enzymes, including CBH Ib CBH IIb, EG II, EG VI, ?-glucosidase, and xylanase II in conjunction with previously identified enzymes CBH Ia, CBH IIa (previously described as Endo 43), and EG V. These enzyme compositions demonstrate an extremely high ability to convert lignocellulosic biomass (e.g., Avicel, cotton, Douglas fir wood pretreated by organosolv) to glucose. CBH Ia and IIb, which both have a cellulose-binding module (CBM) displayed a pronounced synergism with three major endoglucanases (EG II, EG V, EG VI) from the same fungus in hydrolysis of cotton as well as a strong synergy with each other. The enzyme compositions are effective in hydrolysis of the lignocellulosic biomass.

Abstract: The present invention relates to a valencene synthase, to a nucleic acid encoding such valencene synthase, to a host cell comprising said encoding nucleic acid sequence and to a method for preparing valencene, comprising converting farnesyl diphosphate to valencene in the presence of a valencene synthase according to the invention.

Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

Abstract: The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca2+ dependency, specific activity, and solubility, in particular under production conditions.

Abstract: A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.

Abstract: The present invention relates to a novel epitope to convert T cell to type 2 helper T (TH2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody.

Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acid encoding the proteins and methods of use of these nucleic acids.

Abstract: The present invention relates to compositions that can be used in hydrolyzing biomass such as compositions comprising a polypeptide having ?-glucosidase activity, methods for hydrolyzing biomass material, and methods for improving the stability and saccharification efficacy of a composition comprising such ?-glucosidase polypeptides and/or activity.

Abstract: The present invention relates to a novel epitope to convert T cell to type 17 helper T (TH17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method, for enhancing immunity using the antibody.

Abstract: Prolyl and lysyl hydroxylases isolated from Mimivirus are described. These are able to hydroxylate collagen. Isolated nucleic acids coding for the mentioned hydroxylases are incorporated into suitable vectors and used to express these hydroxylases in host cells, e.g. E. coli. Furthermore a method of manufacturing hydroxylated collagen in a host cell is described. The hydroxylases and the recombinantly expressed hydroxylated collagen are useful in clinical settings and biotechnology applications.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved stability and/or improved wash performance in any detergent in comparison to their wild type parent enzymes. The enzymes are well-suited for use in any detergent and for some in especially liquid or solid shaped detergent compositions.

Abstract: The invention in principle pertains to the field of recombinant manufacture of alkaloids and, in particular, cycloclavine. It provides polynucleotides for the gene cluster of enzymes involved in the biosynthesis of cycloclavin as well as vectors and host cells comprising such polynucleotides. Also provided are polypeptides encoded by the said polynucleotides which can be applied in a method for the manufacture of cycloclavine also encompassed by the present invention.

Abstract: A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.

Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.

Abstract: The present invention relates to alpha-amylases, nucleic acids encoding the alpha-amylases, methods of producing the alpha-amylases, and methods of using the alpha-amylases.

Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract: The invention relates to recombinant cells and their use in the production of 3,4-dihydroxybutyrate, 2,3-dihydroxybutyrate and 3-hydroxybutyrolactone.

Abstract: A recombinant protein having luciferase activity and at least 60% similarity to a wild-type luciferase wherein in the sequence of the enzyme, the amino acid residue corresponding to residue 357 in Photinus pyralis luciferase is mutated as compared to the corresponding wild-type luciferase, such that the luciferase enzyme is able to emit light at a different wavelength as compared to the corresponding wild-type luciferase and/or has enhanced thermostability as compared to the corresponding wild-type luciferase. In general, the residue corresponding to 357 in Photinus pyralis luciferase is changed from an acidic amino acid to a non-acidic amino acid and preferably an uncharged polar amino acid such as tyrosine. Mutant luciferases in accordance with the invention can produce a large (50 nm) wavelength shift in emitted light and have good thermostability. The resultant colour shift can be reversed by addition of coenzyme A. These properties make the mutant particularly useful in a variety of assays.

Abstract: The invention relates to recombinant expression of a variant form of a fungal C1 strain ?-glucosidase. The invention also relates to the generation of fermentable sugars from biomass and the production of biofuels by fermentation of the sugars using genetically modified organisms expressing the ?-glucosidase variant. The invention provides methods for producing a fermentable sugar, such as glucose, from cellobiose by contacting cellobiose with a recombinant ?-glucosidase variant protein, such as a variant protein secreted by a recombinant host cell into culture medium. Methods of the invention may be used for conversion of a biomass substrate to a fermentable sugar, and ultimately to ethanol or other biofuel.

Abstract: The present invention relates to isolated polypeptides having cellulolytic activity or hemicellulolytic activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity, catalytic domains, and cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains, and cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, or cellulose binding domains.

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.

Abstract: The present invention relates to the production of sugar hydrolysates from cellulosic material. The method may be used, for example for producing fermentable sugars for the production of bioethanol from lignocellulosic material. Cellulolytic enzymes and their production by recombinant technology are described, as well as uses of the enzymes and enzyme preparations.

Abstract: The object is to provide a transformant which can produce a heterologous protein having a structurally controlled O-linked sugar chain having an O-Man-Gal disaccharide structure, a method for producing the transformant by using Schizosaccharomyces pombe as the host, and provide a host for producing the transformant and a method for producing an O-glycosylated heterologous protein. An Schizosaccharomyces pombe host having no omh1 gene or an inactivated omh1 gene in its chromosomes for producing an O-glycosylated heterologous protein having an O-linked sugar chain having an O-Man-Gal disaccharide structure by expression of the heterologous protein by a genetic engineering technique and subsequent glycosylation of the expressed heterologous protein. A transformant from the host, a method for producing the transformant and a method for producing an O-glycosylated heterologous protein by using the transformant.

Abstract: Provided herein are host cells comprising carbonic anhydrase activity, wherein the cells are capable of producing C4-dicarboxylic acid. Also provided are methods of producing C4-dicarboxylic acid comprising (a) cultivating the host cells having carbonic anhydrase activity in a medium under suitable conditions to produce C4-dicarboxylic acid; and (b) recovering the C4-dicarboxylic acid.

Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 1,4-butanediol (BDO). Also provided herein are methods for using such an organism to produce BDO.

Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.

Abstract: The present invention relates to chimeric GH61 polypeptides having cellulolytic enhancing activity. The present invention also relates to polynucleotides encoding the chimeric GH61 polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the chimeric GH61 polypeptides.

Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.

Abstract: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.

Abstract: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a fatty acid or fatty acid derived product, wherein the modified microorganism produces fatty acyl-CoA intermediates via a malonyl-CoA dependent but malonyl-ACP independent mechanism

Abstract: In one aspect there is provided a method for producing a recombinant enzyme capable of hydrolysing chlorophyll or a chlorophyll derivative, comprising a step of intracellular expression of the recombinant enzyme in a eukaryotic host cell.

Abstract: The present invention provides fungal xylanase and/or beta-xylosidase enzymes suitable for use in saccharification reactions. The present application further provides genetically modified fungal organisms that produce xylanase and/or beta-xylosidases, as well as enzyme mixtures exhibiting enhanced hydrolysis of cellulosic material to fermentable sugars, enzyme mixtures produced by the genetically modified fungal organisms, and methods for producing fermentable sugars from cellulose using such enzyme mixtures.

Abstract: The present invention relates to enzyme compositions for high temperature saccharification of cellulosic material and to uses thereof.

Abstract: A method for suppressing a reduction in an endoglucanase activity in the presence of a surfactant, characterized by modifying a protein having the endoglucanase activity in which the N-terminus is an amino acid other than pyroglutamic acid, to a protein having the N-terminus of pyroglutamic acid, is disclosed. Further, a modified protein having an endoglucanase activity wherein the N-terminal amino acid is converted into pyroglutamic acid by an amino acid modification, a polynucleotide encoding the protein, an expression vector comprising the polynucleotide, a host cell transformed with the expression vector, and a process for producing the protein by cultivating the host cell, are disclosed.

Abstract: The present invention relates to the cloning and sequence of a biosynthetic gene cluster from Streptomyces platensis that produces platensimycin and platencin. Also provided are engineered micro-organisms for the production of these compounds, and analogs thereto, as well as methods of screening for compounds with anti-bacterial activity.

Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

Abstract: The present invention relates to a method for producing terpenes in fungi, wherein a terpene biosynthetic gene cluster having terpene biosynthetic genes and regulatory regions operably linked to said genes is activated. The invention relates also to a terpene biosynthetic gene cluster and regulatory regions of such terpene biosynthetic gene cluster usable is production of terpenes, use of regulator for regulating the terpene production and use of Aspergillus nidulans FGSC A4 for producing terpenes. The method of invention provides higher yields of enriched terpene product without essential amount of side-products.

Abstract: The present invention relates to a recombinant fungus comprising an enzyme which catalysts the conversion of malic acid to fumaric acid in the cytosol. The invention further relates to a process for the production of a dicarboxylic acid such as fumaric acid and succinic acid, wherein the recombinant fungus is used.

Abstract: The present disclosure provides mutant cells for the secretion of proteins and for the degradation of lignocellulosic biomass. Methods for the use of these cells are also provided. Specifically, the utility of combined genetic deletions of ?-glucosidases and the catabolite repressor gene creA/cre-1 for protein secretion in fungal and yeast cells is disclosed.

Abstract: The invention provides certain embodiments relating to methods and compositions for incorporating non-natural amino acids into a polypeptide or protein by utilizing a mutant or modified aminoacyl-tRNA synthetase to charge the non-natural amino acid to a the corresponding tRNA. In certain embodiments, the tRNA is also modified such that the complex forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with unmodified tRNA/aminoacyl-tRNA synthetase pairs.

Abstract: It is intended to provide base sequences participating in the regulation of the expression of a promoter. It is also intended to modify a promoter based on the base sequence data to give a modified promoter having a high expression activity. Namely, a modified promoter constructed by inserting a first DNA fragment containing CCAATNNNNNN (SEQ ID NO:1) (a first base sequence) and a second DNA fragment containing CGGNNNNNNNNNGG (SEQ ID NO:2) (a second base sequence) into a promoter functioning in a filamentous fungus, wherein N in the base sequence denotes A (adenine), G (guanine), C(cytosine), or T (thymine).